Cetera Advisors LLC decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 2.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,537 shares of the medical instruments supplier’s stock after selling 284 shares during the quarter. Cetera Advisors LLC’s holdings in Becton Dickinson and were worth $2,405,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Duality Advisers LP increased its position in shares of Becton Dickinson and by 12.7% during the 1st quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock worth $4,365,000 after purchasing an additional 1,970 shares during the last quarter. Meridian Wealth Advisors LLC grew its position in Becton Dickinson and by 2.7% in the 1st quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock valued at $946,000 after acquiring an additional 99 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $2,062,000. Black Diamond Financial LLC purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $562,000. Finally, Findlay Park Partners LLP boosted its stake in shares of Becton Dickinson and by 8.3% in the 2nd quarter. Findlay Park Partners LLP now owns 2,220,000 shares of the medical instruments supplier’s stock valued at $559,462,000 after buying an additional 170,000 shares during the period. Hedge funds and other institutional investors own 84.26% of the company’s stock.
Several equities analysts have recently issued reports on the company. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. Wells Fargo & Co boosted their target price on Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Piper Jaffray Companies reduced their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Raymond James boosted their target price on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $266.55.
In other news, Director Claire Fraser sold 1,429 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total value of $347,618.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 37,249 shares of company stock worth $9,616,803 over the last 90 days. Insiders own 0.12% of the company’s stock.
NYSE:BDX traded up $0.40 during trading hours on Friday, reaching $262.55. 4,381 shares of the stock were exchanged, compared to its average volume of 899,889. The stock has a market capitalization of $70.77 billion, a P/E ratio of 23.78, a P/E/G ratio of 1.89 and a beta of 1.13. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The firm has a 50 day simple moving average of $252.38 and a 200-day simple moving average of $245.32.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter last year, the business posted $2.91 EPS. The business’s revenue was up 1.7% on a year-over-year basis. As a group, analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Quantitative Easing
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.